Advanced Enzyme Technologies Limited released its Integrated Annual Report for FY 2025-26, presenting a comprehensive overview of its financial performance, business operations, sustainability initiatives, and governance structure. The report covers the financial year ended March 31, 2026, and includes both standalone and consolidated financial statements audited by MSKA & Associates LLP.

Financial Performance

The company delivered strong consolidated financial results for FY26. Revenue from operations rose 17% to ₹7,458 million from ₹6,369 million in FY25, with international sales of ₹3,731 million (up 8%) and domestic sales of ₹3,727 million (up 28%), each contributing 50% to total revenue. On a standalone basis, revenue from operations grew 29% to ₹4,528 million from ₹3,514 million in FY25.

The following table summarises key consolidated financial metrics:

Standalone profitability also improved markedly. EBITDA stood at ₹1,104 million (24%) versus ₹706 million (20%) in FY25. Standalone PAT increased 29% to ₹1,318 million from ₹1,024 million. Other income for FY26 was ₹348 million compared to ₹330 million in FY25, while depreciation and amortisation stood at ₹401 million versus ₹365 million in FY25. Finance costs declined to ₹26 million from ₹35 million. Return on Equity was 11% in FY26 compared to 10% in FY25.

Key Financial Ratios

Business-wise Performance

The Human Nutrition vertical remained the largest revenue contributor at ₹4,674 million, reflecting 15% year-on-year growth. Within this segment, Serratiopeptidase contributed 23% to consolidated revenue with sales of ₹1,732 million, up from ₹1,193 million in the prior year. Consolidated probiotic revenues stood at ₹216 million. The Biocatalysts segment reported revenues of ₹247 million versus ₹174 million previously.

The Animal Nutrition vertical delivered revenue of ₹946 million, a 25% year-on-year increase. The Bioprocessing business grew 16% overall. Within it, Food Processing revenues reached ₹967 million (up 19% YoY), while Non-Food Processing revenues were ₹209 million, a marginal growth of 0.2%.

Subsidiary Performance

Dividend and Capital

The Board declared an interim dividend of ₹4 per equity share (face value ₹2 each) for FY26 and recommended a final dividend of ₹1.35 per equity share, subject to shareholder approval at the 37th Annual General Meeting scheduled for July 31, 2026. The paid-up share capital stood at ₹223.85 million as of March 31, 2026, comprising 111,926,800 equity shares.

R&D and Innovation

Consolidated R&D expenditure for FY26 was ₹246 million (3.30% of net sales), compared to ₹248 million (3.86% of net sales) in FY25. On a standalone basis, total R&D expenditure was ₹355.92 million (7.86% of net sales) versus ₹328.39 million (9.34% of net sales) in FY25. The company filed three patent applications and three GRAS dossiers with the US FDA during the year. A new large-scale R&D centre is under development in Nashik, expected to be operational in the latter half of FY 2026-27.

Operations, Sustainability and Governance

Exports accounted for 33.58% of standalone revenues, with the company exporting to 52 countries across five continents. The company operates four plants and two offices nationally. Total energy consumed from renewable sources was 1,471 GJ, with an installed solar capacity of 510 kW. Scope 1 GHG emissions stood at 25,988 tCO2e and Scope 2 at 8,974 tCO2e in FY26. The company recycled 33% of water consumed and reused 337 MT of waste.

The workforce comprised 400 employees and 362 workers at year-end, with women representing 22.25% of total employees. The employee retention rate was 86%. The company spent ₹647 million towards employees during FY26. The Board comprised nine directors as of March 31, 2026, with Mr. Vasant Rathi as Chairman and Non-Executive Director and Mr. Mukund Kabra as Whole-time Director. ICRA assigned [ICRA]AA-(Stable) for long-term fund-based cash credit and [ICRA]A1+ for short-term non-fund based limits.

During FY26, the Board approved collaboration for a group captive wind power project through a Special Purpose Vehicle, with an investment of up to 26% equity stake, to avail wind power of up to 1.9 MW for plants at Sinnar and Pithampur. Advanced Nutrazyme Private Limited was incorporated on July 4, 2025 as a wholly owned subsidiary to expand the company's presence in the nutrition and wellness segment under the WELLFA brand.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE837H01020/32b6ab3b-2453-4420-b4e1-cc3e815ba126.pdf

Chandrakumar Laxminarayan Rathi, a promoter of Advanced Enzyme Technologies Limited , has declared that he and Persons Acting in Concert (PAC) have not created any new encumbrances during the financial year. The disclosure, submitted to the stock exchanges and the company's Audit Committee, confirms that no direct or indirect charges have been made other than those already disclosed.

The declaration was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any encumbrance on shares held by them or PACs to ensure transparency for shareholders.

The filing, dated April 01, 2026, identifies the following entities as part of the Promoter Group acting in concert with Rathi:

The document was digitally signed by Chandrakumar Laxminarayan Rathi on April 07, 2026, and addressed to BSE Limited, National Stock Exchange of India Limited, and the Audit Committee of Advanced Enzyme Technologies Limited.